A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Albenza Side Effects, and Drug Interactions - Albendazole
Albenza Side Effects, and Drug Interactions - Albendazole
SIDE EFFECTS
The adverse event profile of albendazole differs between hydatid disease and
neurocysticercosis. Adverse events occurring with a frequency of ≥1% in
either disease are described in the table below.
These symptoms were usually mild and resolved without treatment. Treatment
discontinuations were predominantly due to leukopenia (0.7%) or hepatic abnormalities
(3.8% in hydatid disease). The following incidence reflects events that were
reported by investigators to be at least possibly or probably related to albendazole.
Adverse Event Incidence ≥1% in Hydatid Disease
and Neurocysticercosis
|
Adverse
Event
|
Hydatid Disease |
Neurocysticercosis |
|
Abnormal Liver
Function Tests
|
15.6 |
<1.0 |
|
Abdominal Pain
|
6.0 |
0 |
|
Nausea/Vomiting
|
3.7 |
6.2 |
|
Headache
|
1.3 |
11.0 |
|
Dizziness/Vertigo
|
1.2 |
<1.0 |
|
Raised Intracranial Pressure
|
0 |
1.5 |
|
Meningeal Signs
|
0 |
1.0 |
|
Reversible Alopecia
|
1.6 |
<1.0 |
|
Fever
|
1.0 |
0 |
The following adverse events were observed at an incidence of <1%:
Hematologic: Leukopenia. There have been rare reports of
granulocytopenia, pancytopenia, agranulocytosis, or thrombocytopenia. (See WARNINGS
.)
Dermatologic: Rash, urticaria.
Hypersensitivity: Allergic reactions.
Renal: Acute renal failure related to albendazole therapy
has been observed.
DRUG INTERACTIONS
Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide
were about 56% higher when 8 mg dexamethasone was coadministered with each dose
of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean
maximum plasma concentration and area under the curve of albendazole sulfoxide
by about 50% in healthy subjects (n=10) compared with a separate group of subjects
(n=6) given albendazole alone. Mean T max and mean plasma elimination
half-life of albendazole sulfoxide were unchanged. The pharmacokinetics of praziquantel
were unchanged following coadministration with albendazole (400 mg).
Cimetidine: Albendazole sulfoxide concentrations in bile and cystic
fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine
(10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.
Theophylline: The pharmacokinetics of theophylline (aminophylline 5.8
mg/kg infused over 20 minutes) were unchanged following a single oral dose of
albendazole (400 mg) in 6 healthy subjects.
top
